A low-molecular-weight inhibitor of the neutral proteinase from rat intestinal smooth muscle

The Biochemical Journal
|February 1, 1980
PubMed

Insights

Researchers identified a novel low-molecular-weight inhibitor in rat intestinal smooth muscle. This inhibitor specifically targets a neutral trypsin-like muscle proteinase, suggesting a role in regulating intracellular protein degradation.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Physiology

Background:

  • Rat intestinal smooth muscle contains endogenous inhibitory activity.
  • This activity is directed against a previously described neutral trypsin-like muscle proteinase.
  • Contamination by other inhibitors is unlikely.

Purpose of the Study:

  • To characterize the endogenous inhibitory activity in rat intestinal smooth muscle.
  • To isolate and purify the low-molecular-weight inhibitory component.
  • To investigate the inhibitory mechanism and specificity.

Main Methods:

  • Resolution of inhibitory activity into high- and low-molecular-weight components.
  • Purification of the low-molecular-weight component to homogeneity.
  • Enzyme inhibition assays to determine specificity and mechanism (competitive inhibition).

Main Results:

  • A homogeneous low-molecular-weight inhibitor (approx. 9000 Da) was isolated, stable across a wide pH range (3-11).
  • The inhibitor competitively inhibited the target muscle proteinase (Ki ≈ 1 µM) but not other tested proteinases.
  • Leupeptin also competitively inhibited the muscle proteinase (Ki ≈ 0.3 µM), while other small proteins had minimal effect.

Conclusions:

  • A specific, low-molecular-weight inhibitor of the rat intestinal muscle proteinase exists.
  • This inhibitor is distinct from common proteinase inhibitors and small peptides.
  • It may play a role in modulating intracellular protein degradation by the muscle proteinase.

Related Concept Videos

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...